CytoMed has generated the critical cell banks for the iPSC-derived hybrid of gamma delta T and Natural Killer cell technology and is currently undergoing process development into a potentially very ...

TD Cowen began coverage on Palvella Therapeutics shares, assigning a Buy rating and setting a price target of $44.00. The stock, currently trading at $13.89, has already shown strong momentum with a ...

Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of ...

Research analysts at Zacks Research increased their Q1 2025 earnings per share estimates for shares of Nektar Therapeutics in a note issued to investors on Wednesday, January 29th. Zacks Research ...

Natural products are small molecules produced naturally by any organism including primary and secondary metabolites. They include very small molecules, such as urea, and complex structures, such ...

As you age, less estrogen also means less moisture in your vaginal walls. There are no natural "cures" for age-related vaginal dryness, but there are some ways to increase wetness naturally. Any ...

The latest to join the ranks is the so-called “natural Mounjaro” drink for weight loss. Recipes vary slightly depending on which one you find, but the natural Mounjaro drink generally consists of ...

CNBC's Angelica Peebles talks to Structure Therapeutics CEO Ray Stevens about ... Here are 8 of the best natural wonders I've seen. 'Stay at home': More than 1,000 UK and Ireland flights cancelled ...

Revance Therapeutics, Inc. faces financial struggles and competition, leading to a proposed takeover by Crown Labs, initially valued at $6.66 per share, later reduced to $3.10. Teoxane ...

The bad news is that the bloom may be coming off the GLP-1 rose, which is presumably the reason why not only Eli Lilly but Novo Nordisk and Viking Therapeutics stock are suffering this morning.

Despite the competitive threat posed by Eli Lilly’s acquisition of Scorpion Therapeutics’ STX-478, which has shown promising efficacy in several cancer types, Relay Therapeutics’ RLY-2608 ...